To determine if excessive osteoclastic-mediated bone resorption (BR) is an early tumor-induced event in multiple myeloma (MM), BR was assessed at first presentation on quantitative bone biopsy in 87 individuals evaluated for monoclonal gammopathy of undetermined significance (MGUS) and reinterpreted according to the presenting features and subsequent follow-up evaluation. As a reference population, 48 patients with previously untreated overt MM were evaluated under similar conditions. The median level of BR was significantly higher in 48 overt MM versus 87 MGUS patients (12.2% ~5 . 1 % [normal level, <6%1, P < .01). Actually, 9390 of overt MM patients had an excessive BR versus 45% of MGUS patients at presentation (P < .01). According to simple presenting parameters (> or <5%0 plasma cells within the bone marrow, presence or absence of mild anemialneutropenia), 31 individuals were classified as lowrisk MGUS. 32 high-risk MGUS, and 24 indolent MM. An excessive BR was observed in 16% of low-risk MGUS, 46% of high-risk MGUS ( P < .01 v low-risk MGUS), 79% of indolent MM ( P < .05 v high-risk MGUS), and 9390 of overt MM patients. Of major interest, the level of BR in indolent MM
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N CONTRAST TO what is observed in the majority of I B-cell malignancies, lytic bone lesions and hypercalcemia are hallmarks of overt multiple myeloma (MM).' A few patients never develop lytic bone lesions during the course of the disease, and sclerotic bone lesions remain exceptional.* The extent of such lesions on bone radiography is highly related to myeloma cell mass at diagnosis3 Futhermore, in patients with indolent low-cell-mass MM, the presence of one lytic bone lesion is a major criterion for predicting disease progression within a few months4 Finally, a recent reappraisal of the predictive value of bone involvement with regard to disease progression has emphasized magnetic resonance imaging to detect both early bone involvement and disease progression.' Taken together, all these studies stress the specificity of bone involvement in patients with MM and its value in predicting early disease extent and severity.
For several years, we and others have tried to analyze the mechanisms of bone lesions in MM. An excessive osteoclastic-mediated bone resorption (BR) has been shown to be an almost constant feature in patients with MM at the histologic and this abnormal process is mediated by soluble evaluation of MGUS patients, an excessive BR at presentation was observed in 52% of MGUS cases that turned out to be unstable or developed subsequent MM, but in only 4%
of stable MGUS ( P < .01). More precisely the level of BR of low-risk MGUS that either turned out to be unstable or that developed into MM was significantly higher at presentation than that of subsequent stable MGUS (4.4% ~2 . 9 %~ P < .051.
The same difference was observed in both high-risk MGUS and indolent MM according to subsequent follow-up studies (8.1% V3.490 and 11.740 ~6 9 0 , respectively, P< .05). Of major interest, the level of BR in 11 stable high-risk MGUS cases actually fulfilling the diagnostic criteria of smoldering MM was very low (3.4%) and similar to that in stable low-risk MGUS (2.9%). We conclude that a quantifiable excess of BR in MGUS is significantly associated with progression and thus is an early symptom of malignancy in these individuals. 0 1996 by The American Society of Hematology.
factors of both tumoral and environmental origin (ie, osteoclast-stimulating factors [OSF])' (reviewed in Bataille et all5) . Concurrently with what has been observed with new imaging technology and to assess whether an excessive BR is an early event in MM enabling diagnosis of malignancy in individuals presenting with a monoclonal gammopathy of undetermined significance (MGUS), the current study was planned. Using bone histomorphometry, we evaluated BR in 87 individuals with MGUS. Correlations obtained with presenting features and subsequent follow-up evaluations allow us to conclude that an excessive BR is clearly an early symptom of malignancy in such individuals. The consequences of this observation have been discussed in connection with our knowledge of the MM cytokine network."
MATERIALS AND METHODS

Patients
Eighty-seven individuals with MGUS were included in this study, of whom 26 had been studied previously." These individuals were referred to one of us (R.B.) because of the recent discovery of their MGUS, although no obvious clinical symptom of overt MM had been detected. They were included in the study because they had a quantitative bone biopsy allowing histomorphometric studies at the time of their first evaluation. Only some of our individuals with MGUS were able to have such an evaluation at presentation. Thus, this MGUS population does not represent consecutive individuals with MGUS referred to our institution.
The first evaluation mainly included the following items: age, sex, physical examination, bone survey on radiography, Ig type, lightchain subtype, hemoglobin, white blood cell and platelet counts, serum calcium, serum creatinine, serum and/or urinary monoclonal component level (grams in the serum or grams per day in urine), bone marrow smears, and bone histomorphometry (details to follow). The median age was 63 years (range, 31 to 80), and the sex ratio of males to females was 0.75. Sixty-six individuals had IgG MGUS and 21 IgA. We excluded from this study those with IgM MGUS. Fifty-eight individuals had K light-chain subtype and 29 A light-chain. Independently of the results of quantitative bone biopsy at the time of the first evaluation, individuals with MGUS were stratified as low-risk MGUS, high-risk MGUS, or indolent MM according to simple criteria: greater than or less than 5% plasma cells on bone marrow smears and presence (or not) of a mild hematologic involvement on blood cell counts.
A standard population of 48 previously untreated patients with overt MM was used as a population of reference.14 These patients had at least one major symptomatic lytic bone lesion on radiography and/or less than 10 g/dL hemoglobin.
Methods: Bone Histomorphometry
Quantitative histology of bone changes was performed as previously described on undecalcified transiliac bone biopsy specimens. 8, 9 Bone biopsies were performed under local anesthesia from a standardized point 2 cm below the iliac crest and 2 cm behind the anterosuperior iliac spine. The transiliac bone cores were 8 mm in diameter. The specimens were immediately fixed in ice-cold, phosphate-buffered Formalin, pH 7.4, and kept for 24 hours at 4°C. They were then dehydrated over a period of 36 hours in pure acetone at 4°C.
Biopsy specimens were embedded in a mixture of purified glycol and methyl methacrylates. The infiltration of bone cores and the embedding process were performed in a cold environment to preserve boneenzyme activities. Sections 7 pm in thickness were cut dry using a Junk (Heidelberg, Germany) type-K microtome with HK3 tungsten knives. Stainings for routine histomorphometry were performed by a modification of the Mallory-Goldner procedures on eight nonserial sections. Six additional nonserial sections were stained for the osteoclastic tartrate-resistant acid phosphatase and were counterstained with phosphomolybdic aniline blue.
Measurements were made on a semiautomatic system developed in the laboratory (digitizing tablet connected to a COMMODORE CBM 4032 microcomputer (Data Sud, Montpellier, France) and an automatic numerized image analyzer: VMWlO MOTOROLA 68000-Fairchild 3000 CCD camera; Digipet Reichert, Heidelberg, Germany).
The following trabecular bone histomorphometric parameters were considered for the current analysis according to the American Society for Bone and Mineral Research nomenclature: eroded surfaces per bone surfaces ([ES/BS] ie, the percentage of trabecular surfaces where marks of a previous resorption are visible, regardless of whether they contain osteoclasts) and the number of osteoclasts on the trabeculae ([OC/B.Ar] per millimeter squared), which was evaluated by histoenzymology (acid phosphatase).
All analyses were blindly performed by one of us (D.C.). The results were compared with those of age-and sex-matched normal 
Statistical Analyses
For statistical analyses, we used the xz method with Yates correction when necessary, Fisher's exact test, Wilcoxon's test (ie, ranksum test), and the median test.
RESULTS
Description and stratijication of individuals with MGUS at presentation. Independently of the results of quantitative bone biopsy at the time of the first evaluation, individuals with MGUS were stratified according to simple criteria: greater than or less than 5% plasma cells on bone marrow smears and presence (or not) of a mild hematologic involvement on blood cell counts.
Thirty-one individuals were classified as low-risk MGUS. Their major features are outlined in Table 1 . They were selected because they presented less than 5% plasma cells within the bone marrow. Actually, 60% lacked any visible plasma cells on bone marrow smears. Blood cell counts and bone survey were strictly normal. Monoclonal IgG or IgA levels ranged from 0.3 to 3.2 g/dL (median, 1.7).
Thirty-two other individuals were classified as high-risk MGUS. Their major features are outlined in Table 2 . They were selected because they presented more than 5% plasma cells within the bone marrow (median, 10%; range, 6% to 50%). Blood cell counts and bone survey were strictly normal. Monoclonal IgG or IgA levels ranged from 0.8 to 4.61 g/dL (median, 2.7).
Twenty-four individuals were classified as indolent MM. Their major features are outlined in Table 3 . They were selected because they presented a mild anemia (hemoglobin > I O and <13 g/dL, 14 cases), neutropenia, unexplained weight loss, one asymptomatic lacuna on bone survey, or a Bence-Jones protein (BJP) more than 1 g/d in the other 10 cases (Table 3 ). Bone marrow invasion by malignant plasma cells ranged from 6% to 80% (median, 28%). Monoclonal IgG or IgA levels ranged from 0.62 to 6.4 g/dL (median, 2.66). Although indolent, these individuals fulfilled the diagnostic criteria of stage I MM.' These data are summarized in Table 4 .
Individuals with low-risk MGUS were evaluated once or twice per year with a median follow-up period of 5 years (range, 1 to IS), and those with high-risk MGUS, every 3 to 6 months with a median follow-up period of 2 years (range, 1 to 9). Bone resorption in normal individuals, in strati3ed MGUS, and in overt MM. In normal individuals, the percentage of ES/BS was 3.6% +-1.1 %." In our reported experience, there was no evidence of an increase in EB/BS with advancing age. Thus, a BR of 6% or greater (2 SD above the mean value) was defined as an excessive BR ( P < .05).
The median level of BR was significantly increased in 48 patients with overt MM ( P < .01) and was significantly higher than in 87 MGUS patients (12.2% for ES/BS v 5.1 %, P < .01; Fig 1) . Actually, 93% of overt MM cases presented an excessive BR, ie, ES/BS 6% or greater, versus 45% of overall MGUS cases, at the time of their first evaluation ( P < .01). Thus, a majority of MGUS cases retained a BR within the normal range, whereas almost all patients with overt MM had an excessive BR. However, it was already striking that some individuals with MGUS presented an excessive BR as marked as that of patients with overt MM. When thc simple stratification of individuals with MGUS For was considered, striking differences in terms of BR were observed between the different categories of individuals. Indeed, an excessive BR was observed in 16% of individuals with low-risk MGUS, 46% of those with high-risk MGUS (P < .01 v low-risk MGUS), and 79% of those with indolent MM (P < .05 v high-risk MGUS) (Fig 2) . Of major interest, the median level of BR in indolent MM ( I I .2%) was found to be as high as that in overt MM ( I 2.2%) and significantly higher than that in both low-risk (4%) and high-risk high-risk MGUS and 80% of indolent MM, close to what was observed in patients with overt MM (Table 4 and Fig  3) .
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M M accordirig to subsequent follow-up evaliration. When the follow-up study of 63 low-or high-risk MGUS cases was considered, it was striking that an excessive BR at the time of first evaluation was observed in 52% of cases that turned out to be unstable or that developed subsequent indolent or overt MM (Fig 3) , but only in 4% of stable MGUS cases (P < .01). The level of BR was 6.3% in the first category of individuals and 2.9% in the second stable category (P < .05). When the follow-up study of low-and high-risk MGUS cases was considered separately, a similar observation was possible. Indeed, the level of BR of seven low-risk MGUS cases that turned out to be unstable or that developed subsequent MM was significantly higher at presentation than that of 13 low-risk MGUS cases stable for 5 to IS years (4.4% v 2.9% P < .OS; Fig 4) . The same significant difference was observed in individuals with high-risk MGUS. Indeed, the level of BR of high-risk MGUS cases that tumed out to be unstable (n = 7) or that developed subsequent MM (n = 13) was significantly higher at presentation than that of 1 1 stable high-risk MGUS cases (8.1% v 3.4%, P < .01; Fig 5) . Of major interest, the level of BR of these 11 stable high-risk MGUS cases actually fulfilling the diagnostic criteria of smoldering MMIR was very low (3.4%) and similar to that of stable low-risk MGUS (2.9%). Highrisk MGUS cases that turned out to be unstable or that developed subsequent MM had a higher BR (8.1 %) than low-risk MGUS cases that similarly tumed out to be unstable or that developed subsequent MM (4.4%. P < .02). In high-risk MGUS cases that developed overt MM with lytic bone lesions, there was a trend for a level of BR (1 1.7%) higher than that of high-risk MGUS cases that turned out to be simply unstable or developed indolent MM @.I%, P < .1).
Finally, to support the conclusion that the changes in BR levels we observed reflected disease status in individual patients rather than completely different patient populations, serial studies were performed in two individual patients. They each showed a significant increase of BR during the transition from MGUS to MM (Table 5) .
Among 24 patients stratified initially as indolent MM, four were lost to follow-up evaluation, 12 developed overt MM within 1 year, characterized by a significant anemia in 10 cases (hemoglobin < IO g/dL) or by the occurrence of bone lesions in two cases, and six remained stable for at least 1 year (range, 1 to 7 y). Of note, the median level of BR in those who developed overt MM ( 1 1.7%) was significantly higher than in those who remained stable (6%. P < .05). In conclusion, the level of BR of MGUS at presentation was always significantly higher and generally abnormal in cases that tumed out to be active (Table 6 ).
When the OC/B.Ar., another parameter of BR directly related to EBBS, was considered in high-risk MGUS and indolent MM (it was not available in low-risk MGUS), a similar observation was possible. A significant increase of OC/B.Ar. was noted in high-risk MGUS cases that turned out to be unstable or developed MM (4.10/mm2) in comparison to stable cases (1.15/mm2, P < .01). Indolent MM also had a significant increase of OC/B.Ar. compared with stable MGUS (3.38/mm2, P < .Ol).
DISCUSSION
Since the pioneering studies by Mundy et a16 and ValentinOpran et al,7 several studies including ours have been devoted to bone cell biology in patients with MM, using histom~r p h o m e t r y .~"~ It has been clearly shown that MM is characterized by an excessive BR in the vicinity of myeloma cells.6"" Whereas bone formation is maintained or somewhat stimulated during the early stages of the disease," disease progression is characterized by a significant inhibition of bone f~r m a t i o n .~. '~ It is this uncoupling process observed at the histologic level and in surrounding myeloma cells, ie, excessive BR with inhibition of bone formation, that is responsible for bone loss and lytic bone lesions in MM." Of major interest, we have shown that this uncoupling bone process was not observed in patients lacking lytic bone lesions or presenting sclerotic bone involvement, despite the presence of an excessive BR in a majority of them.'" When the basic process of BR was more carefully detailed in MM, it was found that the MM-induced bone changes were almost For constantly characterized by significant increases of ( I ) the ES/BS.7~" (2) the osteoclast number. It is now well documented that MGUS can remain stable for many years.".'" However, a significant percentage of cases can progress to showing features of smoldering MM, indolent MM, and even overt MM requiring treatment."."' The delay ranges from a few months to more than 30 years, suggesting that MGUS cases have to be surveyed indefinitely. Thus, at the time of their first evaluation and subsequently, a critical question about MGUS patients is to know Our data showing a very early and abnormal BR in patients with MM are of critical importance for understanding the biology of this disease, ie, the first cellular events occurring within the bone marrow in the case of malignant transformation. The excess of BR we found early in the disease was only observed in the vicinity of plasma cells. We and others have made the same observation in patients with overt MM.'.I4 These data suggest that cell-to-cell contacts and autocrine/paracrine (rather than endocrine/systemic) factors are critical in this process. The same could be said about the early activation of osteoblasts we previously described in patients with MM." Of note, it is now well For personal use only. on October 23, 2017. by guest www.bloodjournal.org From documented that both osteoclasts and osteoblasts can produce tremendous amounts of interleukin-6 (IL-6),23 an essential survival and growth factor for myeloma ~e l l s~~~*~ and a critical factor in bone rem~deling.'~ It is thus clear that myeloma cells find what they need to grow and to stimulate bone cells from the bone cells themselves. IL-10 is a potent inducer of IL-6 in MM*' via a PGE2 loop,*' and is produced in large amounts in the MM intermediate milieu in correlation with the presence of bone lesion^.^^^'^ Although it is not clear whether IL-10 is directly produced by the myeloma cells t h e m~e l v e s ' '~~~~~~ or not,32.33 it is likely that IL-lp and IL-6 play a critical role in the early tumor cell growth and abnormal bone remodeling observed in MM. 34 Considering that normal plasma cells do not produce IL-lp,3s it is critical to understand why myeloma cells can either produce active IL-lp aberrantly or induce active IL-1p production in the bone mircroenvironment. In this context, the evaluation of MGUS will be essential.29 Our current data suggest that it could be important to limit this early excessive BR observed in MM not only to avoid bone loss but also to limit clonal progression. Considering the potential role of IL-Ip in this process, new molecules like IL-1 receptor antagonist, which is able to limit the production of PGE2 and IL-6 in the myeloma intermediate mi lie^,'^ and IL-1 -induced bone resorption3' deserve further investigation. On a more practical point, bisphosphonates able to limit the occurrence of major bone events in patients with overt MM could turn out to be very helpful in these cases of early MM.37-39 It is of major interest that bisphosphonates were recently shown to be able to inhibit IL-1 -induced IL-6 production by human osteob l a s t~.~~ Our approach toward the early malignancy in MM using histomorphometry on a routine basis has been limited by the method itself. For technical reasons, quantitative bone biopsies are performed at a standard site (iliac crest). Furthermore, the excess of BR is only observed in the close vicinity of plasma cells. Thus, the lack of plasma cells within the sample makes the biopsy noninformative in some cases. Finally, such quantitative bone biopsies are not routinely performed daily and cannot be performed in outpatients. Thus, despite significant results, it is difficult to suggest such an approach to evaluate MGUS routinely, although the parameter we used, ie, the percentage of eroded surfaces, is the most simple to evaluate. We have previously shown that parameters of bone formation are modified in early MM; however, such an evaluation required kinetic studies that are more difficult to perform routinely." Thus, considering the importance of detection of such abnormalities of bone remodeling in early MM routinely, further investigation of new sensitive systemic markers of BR is needed. Of note, bone densitometry and urinary deoxypyridinoline could be potential ways of assessing bone remodeling in MGUS individual~.~',~ ' We conclude that a quantifiable excess of BR, which is a constant histologic feature of overt MM, is also an early malignant symptom in individuals with MGUS. This excess of BR is detectable several years before the first clinical symptom of MM. Considering the now well-documented vicious cycle existing between myeloma cell growth and bone remodeling, the inhibition of this early excess of BR with bisphosphonates deserves further investigation because it could improve the follow-up study of such individuals.
